Search results
Showing 101 to 150 of 588 results for pregnancy
ID NG126/01 Question Early pregnancy assessment units: A national evaluation of early pregnancy assessment unit service...
e-cigarettes and pregnancy: Are nicotine replacement therapy or nicotine-containing e-cigarettes effective to help women stop smoking in...
between expectant, medical or surgical management of ectopic pregnancy: In women with ectopic pregnancy, does the type of...
or surgical) and in a variety of clinical settings (for example, early pregnancy assessment unit, gynaecological ward or gynaecological...
e-cigarette use? Are there any specific health effects relating to use in pregnancy, or use by children and young people? Any...
care for them, about the use of nicotine-containing e‑cigarettes during pregnancy? Any explanatory notes(if applicable) For a short...
birth when vaginal micronised progesterone was given to women with early pregnancy bleeding and a history of one or more previous...
viable intrauterine pregnancy: How does the timing and frequency of ultrasound examination affect diagnosis and outcomes of early...
previous pregnancy losses have an increased risk of miscarriage in subsequent pregnancies. Progesterone is essential for...
Recommendation ID NG207/01 Question Prevention of prolonged pregnancy: At what gestational age should induction of labour be offered in...
Recommendation ID NG207/02 Question Prevention of prolonged pregnancy: Based on individual patient data meta-analysis, what is the...
develop in pregnancies that continue after the membranes have ruptured, putting both the woman and the baby at risk. In some such...
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
intervention that may positively influence the transition from maintenance of pregnancy to the onset of labour, reducing the need for...
Pelvic floor dysfunction: prevention and non-surgical management (NG210)
This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Pregnancy and neonates: smokers at booking appointment (IND18)
This indicator covers the proportion of pregnant women who were smokers at the time of their booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG31
This indicator covers the proportion of pregnant women who were smokers at the time of delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG32
Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Heart valve disease presenting in adults: investigation and management (NG208)
This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.
This quality standard covers the induction of labour in hospital outpatient or inpatient settings. It includes advice and care for pregnant women who are considering or having induction of labour. It describes high-quality care in priority areas for improvement.
View quality statements for QS60Show all sections
Sections for QS60
- Quality statements
- Quality statement 1: Women's involvement in decisions about induction of labour
- Quality statement 2: Safety and support for women having labour induced as outpatients
- Quality statement 3: Pain relief
- Quality statement 4: Membrane sweeping for prolonged pregnancy
- Update information
- About this quality standard
This indicator covers the proportion of babies with a screen positive newborn hip result who attend for ultrasound scan of the hips within the designated timescale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG96
This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.
nausea and vomiting in pregnancy: What is the clinical and cost effectiveness of medication for women with nausea and vomiting in...
are in evidence review V: management of unexplained vaginal bleeding in pregnancy. Source guidance details Comes from guidance Antenatal
effectiveness of corticosteroids for women with severe nausea and vomiting in pregnancy? Any explanatory notes(if applicable) For a...
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Pregnancy and neonates: newborn blood spot test communication with 6 weeks of movement in (IND67)
This indicator covers the proportion of babies with a 'not suspected' result for all the conditions tested for by newborn blood spot testing who have a results letter sent to their parents directly from the child health information service (CHIS) within 6 weeks of notification of movement in. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG86
Pregnancy and neonates: newborn blood spot test communication within 6 weeks of birth (IND66)
This indicator covers the proportion of babies with a 'not suspected' result for all the conditions tested for by newborn blood spot testing who have a results letter sent to their parents directly from the child health information service (CHIS) within 6 weeks of birth. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG85
NICE and Cochrane sign collaborative agreement to deliver 'living' guideline recommendations
NICE and Cochrane have today (01st September 2021) signed a collaborative agreement which will help to deliver ‘living’ recommendations across the NICE guideline portfolio.
NICE has today (20 August 2021) issued final draft guidance which now recommends sapropterin (also called Kuvan and made by BioMarin) as an option for treating phenylketonuria (PKU) in pregnant women until they give birth as well as for treating the condition in people until they turn 22.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
Pregnancy and neonates: neonatal deaths or still births (IND21)
This indicator covers the proportion of pregnancies resulting in a neonatal death or still birth. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG34
This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33
NICE publishes final guideline advising on care throughout a woman's pregnancy
The updated antenatal care guideline focuses on women-centred care, informed shared decision making and the role of partners during pregnancy.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support. We have also published a guideline on postnatal care , which covers the topics of emotional attachment and baby feeding.
Recommendation ID CG137/5 Question AEDs and pregnancy: What is the malformation rate and longer term neurodevelopmental outcome of...
Pregnancy and neonates: planned caesarean after 39 weeks (IND24)
This indicator covers the proportion of pregnant women having a planned caesarean section who have the procedure carried out at or after 39 weeks 0 days. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG37
This indicator covers proportion of pregnant women accessing antenatal care who are seen for booking by 10 weeks and 0 days. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG81
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
NICE opens consultation on draft pelvic floor dysfunction guideline recommendations
NICE has today (28 June 2021) published its draft guideline on the prevention and non-surgical management of pelvic floor dysfunction and is seeking stakeholder comments on the draft recommendations.
NICE and PHE publish comprehensive draft guideline to tackle the health burden of smoking
Healthcare staff should give clear and up-to-date information on e-cigarettes to people who are interested in using them to stop smoking, according to draft NICE guideline recommendations out for consultation today. NICE worked with Public Health England to develop this guideline
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
View recommendations for CG138Show all sections
the majority of women and their babies at the end of an uncomplicated pregnancy. However, even after a normal delivery there is a risk...